Stockscreener 앱 받기
9.38
2.07%
0.19
시간 외 거래:
9.54
0.16
+1.71%
Vir Biotechnology Inc 주식(VIR)의 최신 뉴스
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - AOL.com
How Marianne De Backer saved Vir Biotechnology after flu drug failure - The Business Journals
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares - AOL.com
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story - Yahoo Finance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - The Motley Fool
Vir Biotechnology’s SWOT analysis: stock gains momentum on partnership and clinical progress - Investing.com UK
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips - Investing.com Nigeria
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver Congress 2026 - marketscreener.com
VIR: Vir Biotechnology Prepares to Present Trial Data at EASL Co - GuruFocus
Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com - Investing.com South Africa
Vir Biotechnology to present hepatitis delta trial data at EASL - Investing.com UK
Vir Biotechnology to present complete week 96 data from Phase 2 SOLSTICE trial - TipRanks
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 - Business Wire
Boxer Capital Management Boosts Vir Biotechnology Holdings in Q1 2026 FilingNews and Statistics - IndexBox
User | bigspringherald.comVir Biotechnology, Inc.Common Stock (Nasdaq:VIR) Stock Quote - FinancialContent
Vir Biotechnology, Inc.Common Stock (NQ: VIR - FinancialContent
Vir Biotechnology rated buy on strong cash, late-stage drugs, and key partnerships through 2028 - Pluang
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity (NASDAQ:VIR) - Seeking Alpha
SoftBank group reports 10.95M-share stake in Vir Biotechnology (VIR) - Stock Titan
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Vir Biotech May 2026 slides: CHD combo hits 88% viral suppression - Investing.com
Q2 EPS Estimates for Vir Biotechnology Cut by HC Wainwright - MarketBeat
TradingKey - TradingKey
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next - simplywall.st
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - Yahoo Finance
A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress - Yahoo Finance
0.98%
0.12%
자본화:
|
볼륨(24시간):